CHAPTER 8. Arsenic-based Anticancer Agents - Archive ouverte HAL Accéder directement au contenu
Chapitre D'ouvrage Année : 2019

CHAPTER 8. Arsenic-based Anticancer Agents

Résumé

Arsenic-based drugs were widely used in the treatment of infectious diseases in the 1900s, but cancer treatment has advanced with the marketing of Trisenox® (INN: arsenic trioxide) for treatment of acute promyelocytic leukemia in the 2000s. In this chapter, I first review the history of the treatment of cancer by arsenic. In the 17th century, some physicians were convinced that an external application of powder could reduce breast cancer cells. Those adventurous applications led only to tissue necrosis, and we now understand how dangerous it was for the patient. An important step forward was also made with Fowler's solution, which would be orally administered. Afterwards, Cutler and Bradford demonstrated that this solution drastically reduced the number of neutrophils in myelogenous leukemia. The more recent marketing of Trisenox® and its unique efficacy in the treatment of acute promyelocytic leukemia raised questions about the mechanism of action of arsenic in cancer treatment. Finally, this chapter summarizes the major mechanisms that lead to the reduction in growth and proliferation of cancer cells. At a molecular level, arsenic is thought to link to numerous proteins (i.e., via the thiol groups of the amino acid side-chains). We know now that some very specific targets exist that are worthy of study.
Fichier non déposé

Dates et versions

hal-02112897 , version 1 (27-04-2019)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Stéphane Gibaud. CHAPTER 8. Arsenic-based Anticancer Agents. Casini, Angela; Vessières, Anne; Meier-Menches, Samuel M. Metal-based Anticancer Agents, Royal Society of Chemistry, pp.196-214, 2019, 978-1-78801-406-9. ⟨10.1039/9781788016452-00196⟩. ⟨hal-02112897⟩
45 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More